Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Signs Pilot Research Deal with Novartis

NEW YORK, April 19 (GenomeWeb News) - Compugen will study biological interaction networks for Novartis by using a platform for analyzing microarray and other data it intends to develop, the Tel Aviv, Israel-based company said today.

Under the pilot project, Novartis will pay Compugen a one-time fee for the results and obtain exclusive rights to them. Compugen will retain all rights to the platform it plans to develop under the collaboration. Additional information about this platform was not disclosed. Also not immediately clear is how this platform will differ from Compugen's existing LEADS technology, which analyzes array and other data -- inlcuding those supplied by Novartis.

Indeed, in August 2001, Novartis licensed Compugen's LEADS platform and asked the company to design DNA chips. The companies broadened their collaboration to include target validation and RNA interference in September 2002.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.